Neuphoria Therapeutics

NEUP

Biotechnology · Healthcare

Price

$3.91

-0.04 (-1.01%)

Market Cap

$21.1M

Exchange

NASDAQ Global Market

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count falling — buybacks

−97.5% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 65.0M (2021) → 1.6M (2025)

Winston Score History

The full picture

Neuphoria Therapeutics Inc. is a small biotechnology company focused on developing treatments for neurological and psychiatric disorders. Like most early-stage biotech firms, it is working to discover and advance drug candidates through clinical trials rather than selling finished products to patients today. Its main customers, if its drugs succeed, would be patients and healthcare providers dealing with conditions affecting the brain and nervous system.

The company makes little to no product revenue right now, which is typical for clinical-stage biotechs — it relies on funding from investors and potentially partnerships to keep research going. The unusual gross and operating margin figures reflect accounting quirks common to pre-revenue companies rather than actual profitability, and the deeply negative ROIC confirms it is spending more than it earns. The biggest risk Neuphoria faces is the high failure rate of drug development: most experimental treatments never reach approval, and the company will need continued capital to fund its pipeline.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-100.0% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-101.4% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$9M/ year

↓ Declining (-36% vs prior year)

57.5% of revenue

3.2x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

22.5%ownership

Insiders own a meaningful stake in the company

Cash Runway

~15 months

$19M cash & investments

Adequate runway but may need to raise capital within 2 years

Revenue declining

Neuphoria Therapeutics's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

Data not available

Profit after running costs

Operating Margin

N/A

Data not available

Return on the money invested

ROCE

-82.0%

Weak — -82.0% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-140.7%

Shrinking sales (-140.7% YoY)

Profit growth

EPS YoY

-268.4%

Earnings shrinking (-268.4% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.00

Conservative — low debt load (0.00)

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial